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ABSTRACT
The aim of this study was to measure and identify the reactive carbonyl species (RCSs) released in
the blood of humans subjected to hepatic resection. Pre-anesthesia malondialdehyde (MDA)
plasma content (0.36±0.11 nmol/mg protein) remained almost unchanged immediately after
anaesthesia, before clamping and at the 10th min after ischemia, while markedly increased (to
0.59 ±0.07 nmol/mg; p< 0.01, Tukey’s post test) at the 10th min of reperfusion. A similar trend
was observed for the protein carbonyls (PCs), whose pre-anesthesia levels (0.17±0.13 nmol/mg)
did not significantly change during ischemia, while increased more than fourfold at the 10th min
of reperfusion (0.75± 0.17 nmol/mg; p< 0.01, Tukey’s post test). RCSs were then identified as cova-
lent adducts to the albumin Cys34, which we previously found as the most reactive protein
nucleophilic site in plasma. By using a mass spectrometry (MS) approach based on precursor ion
scanning, we found that acrolein (ACR) is the main RCS adducted to albumin Cys34. In basal con-
ditions, the adducted albumin was 0.6 ± 0.4% of the native form but it increased by almost four-
fold at the 10th min of reperfusion (2.3 ± 0.7%; p< 0.01, t-test analysis). Since RCSs are damaging
molecules, we propose that RCSs, and ACR in particular, are new targets for novel molecular treat-
ments aimed at reducing the ischemia/reperfusion damage by the use of RCS sequestering
agents.
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Many hepatic surgery procedures demand the mainten-
ance of the liver in an ischemia condition that can last
between 15 and 50min. Although the surgical techni-
ques have concurred to markedly lower the ischemic
period, hepatic alterations consequent to partial hepa-
tectomy are still frequent [1]. Similarly, during the sev-
eral phases of the hepatic transplantation, the hepatic
tissues are exposed to more or less extended periods of
warm or cold ischemia that can induce its loss of func-
tion or temporary malfunction in 4–10% or 20–25% of
patients, respectively [2–4]. The main cause of the hep-
atic damage consequent to partial hepatectomy or to
liver transplantation is ischemia/reperfusion (I/R) [4]. The
loss of oxygen supply during the ischemic phase deter-
mines the de-energization of mitochondria and the
reduction of intracellular ATP associated with alterations
of the steady state of Naþ, Hþand Ca2þ [5–8]. The
re-introduction of the oxygen supply during reperfusion
causes an increased production of reactive oxygen spe-
cies (ROSs) inducing oxidative stress and mitochondrial
permeability transition [9]. Moreover, activated Kupffer
cells during reperfusion release ROSs, nitric oxide and
pro-inflammatory cytokines such as tumor necrosis fac-
tor-a (TNF-a), monocyte chemotactic protein-1 (MCP-1),
neutrophil-attracting CXC chemokines, and the interleu-
kins (IL)-6, IL-1b, IL-12 and IL-18 [10], which latter inhib-
its the synthesis of the anti-inflammatory cytokine IL-10
[11]. Overall, the I/R occurring during hepatectomy is a
condition of oxidative stress that can induce cell and
organ dysfunction. Among the different mechanisms of
oxidative stress involved in the I/R damage, those
involving the formation of reactive carbonyl species
(RCSs), such as lipid peroxidation products, are gaining
great interest [12]. RCSs are strongly electrophilic
towards endogenous nucleophilic substrates, such as
DNA and proteins, and lead to irreversible covalent
modifications [13]. Miyata and colleagues have defined
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‘‘carbonyl stress’’ as the accumulation in the plasma of
RCSs derived from lipid, carbohydrate and protein car-
bonylation [14]. RCSs derived from lipids and carbohy-
drates possess a longer half-life in respect to free
radicals and ROSs. Moreover, while ROSs are generally
free radicals and/or ionic species, RCSs are neutral mole-
cules able to diffuse through cellular membranes and
therefore to react within sites distant from their produc-
tion site. For this reason, RCSs are not only direct cyto-
toxic but can also mediate and propagate oxidative
stress and tissue damage as second messengers. RCSs
from lipid peroxidation cascade are quite heteroge-
neous and can be divided into three main classes,
namely: (1) the a,b-unsaturated aldehydes, including 4-
hydroxy-2-nonenal (HNE) and acrolein (ACR); (2) di-alde-
hydes, including the well-known lipid peroxidation by
product malondialdehyde and glyoxal; (3) keto-alde-
hydes, such as methylglyoxal [13].
Several studies, both in animal models and in
humans, have reported the increase of RCSs such as free
aldehydes or protein adducts in the liver under I/R dam-
age [15–19]. The usual analytical methods give an over-
all measure of RCS/advanced glycation and lipoxidation
end-products (AGEs/ALEs) content, but do not identify
the specific RCSs or protein substrates involved in the
damaging reaction. Such information is of great value
not only in the setting-up of methods aimed to identify
specific analytics, but also in order to obtain a deep
insight into the damaging mechanism and, thereby, to
rationally design suitable molecular strategies, which
depend on the chemical structure of the RCS involved
[20,21].
The aim of this study was to identify by an off-target
mass spectrometry (MS) approach the main attacking
RCS species formed in the blood of patients subjected
to hepatic resection, with particular focus on serum
albumin modifications.
For this purpose, we applied a MS strategy for the
rapid identification and characterization of albumin
Cys34-covalent modifications, as this residue is highly
sensitive to formation of various post-translational
modifications [22]. This strategy was based on the
precursor ion scanning technique, which is able to
supply a rapid confirmation of targeted or non-tar-
geted compounds with a common moiety, and has
been widely used in drug discovery and develop-
ment [23] and in vitro/in vivo drug-metabolism stud-
ies [24–26]. Furthermore, we have used this approach
also for the rapid identification of free and protein-
bound histidine (His) residues modified by RCS in
urine from Zucker-obese rats [27].
Methods
Chemicals
Custom-synthesized LQQCPF peptide, with 90% purity
was supplied by Sigma–Aldrich (Milan, Italy). ACR was
purchased from Fluka (Buchs, Switzerland). Sequence-
grade modified trypsin was obtained from Promega
(Milan, Italy) and chymotrypsin from Roche Diagnostics
S.p.A. (Monza, Italy); Iodoacetamide (IAA), (±)-threo-1,4-
dimercapto-2,3-butanediol (DTT) from Sigma-Aldrich
(Milan, Italy). LC-grade and analytical-grade organic sol-
vents were from Merck (Bracco, Milan, Italy). LC-grade
water (18 mX) was prepared with a Milli-Q water purifi-
cation system (Millipore, Bedford, MA). All other
reagents were of analytical grade.
Surgery procedures
During the interventions, the following parameters
were routinely monitored: arterial blood pressure
(ABP, radial artery catheter), heart rate (HR), arterial
oxygen saturation and central venous pressure (CVP).
In addition, the radial artery catheter was connected
to MostCare
VR
by means of a pressure transducer to
monitor the uncalibrated blood pressure wave-based
hemodynamic. This monitoring system allows adjunct-
ive measures of cardiac output/index (CO/CI), sys-
temic vascular resistance (SVR/SVRI). The objective of
this monitoring is to ensure adequate perfusion of
vital organs during all stages of intervention and tar-
get therapy. Blood samples for blood gas analysis
(BGA) were drawn for the first time 20min after the
induction of anesthesia and then every 15min. Blood
was collected from the catheters inserted in the
radial artery in conjunction with the hemodynamic
recordings. During the whole surgical time, the fluid
infusions (plasma expanders as well as saline solu-
tions) and vasoactive amines (dopamine, 3–6mcg/kg/
min) were administered as needed to maintain a
mean SAP above 65mmHg and autologous red
blood cells were administrated in order to compen-
sate intra-operative blood losses and maintain hemo-
globin above 10 gr/dL. Metabolic acidosis (pH <7.25
and BE <8mmol/L) was corrected with sodium bicar-
bonate or THAM infusion. Esophageal temperature
was kept within a normal range using elect warming
pads. Mechanical ventilation was initiated with a con-
tinuous flow of 10 L/min, inspired oxygen fraction
(FiO2) of 50%, peak inspiratory pressure of 12 cm
H2O, positive end respiratory pressure of 3 cm H2O,
respiratory rate of 10/min.























































Collection of blood samples
Samples of peripheral blood were obtained with written
consent from patients (n¼ 6) undergoing hepatectomy
for hepatic metastases. Samples (5–10ml) were col-
lected into heparin-coated sterile tubes at the following
stages if the surgical intervention: (1) before administra-
tion of anesthesia (‘‘anesthesia t0’’); (2) before applica-
tion of clamps (‘‘ischemia t0’’); (3) 10min after
application of clamps (ischemia, ‘‘ischemia t10’’); (4)
immediately after release of clamps (reperfusion, ‘‘reper-
fusion t0’’); (5) 10min after start of reperfusion (‘‘reperfu-
sion t10’’). Blood samples aliquots were used to prepare
cell-free blood serum by centrifugation; the serum sam-
ples were immediately frozen and maintained at ÿ80 C
for further analyses. For five patients, a fourth aliquot
was collected at anesthesia t0 and reperfusion t10 time
points and used to detect covalent modifications of
albumin Cys34.
Protein concentration assay
Protein concentration was scored in the samples by the
Bradford assay, using a standard curve of bovine serum
albumin (0–15 lg protein/200 ll volume) [28].
Protein carbonyl (PC) assay
Oxidative modifications in plasma were assessed based
on the carbonyl content using 2-4 dinitrophenylhydra-
zine (DNPH), as previously reported [29]. Reacting with
PC, DPNH forms a Schiff base to produce the corre-
sponding hydrazone, which can be analyzed spectro-
photometrically. Briefly, after incubation with DNPH
(400 ll), plasma (100 ll) was precipitated with
Trichloracetic acid (TCA). The pellet was washed several
times with a 1:1 mixture of ethanol/ethyl acetate, resus-
pended in 500 ll of guanidine hydrochloride and meas-
ured at 370 nm. The PC content was calculated using a
molar extinction coefficient of 22,000 Mÿ 1 cmÿ 1, nor-
malized for protein concentration and expressed in
nmol/mg.
MDA quantification
Malondialdehyde (MDA) was quantified using the thio-
barbituric acid reactive substances (TBARS) assay kit
(Oxitek-ZeptoMetrix Corporation, Buffalo, NY), according
to the manufacturer protocol. Briefly, 100 ll of plasma
were aliquoted in glass tubes (each sample was in tripli-
cate), mixed with reaction buffers and placed in a heat
block at 95 C for 1h. After incubation, samples were
quickly cooled on ice and centrifuged at 3000g for
15min to remove debris. The fluorescence emission of
the recovered supernatants was measured at an excita-
tion wavelength of 530 nm and an emission wavelength
of 550 nm, using a Perkin-Elmer LS55 spectrofluorimeter
(Waltham, MA).
Identification of LQQCPF adduct by LC-ESI-MS
analysis
LQQCPF-adducts were prepared, as described by Aldini
et al. [24], and reduced by incubation with NaBH4 for
60min at 37 C. Human serum albumin (HSA) was iso-
lated from plasma samples by using the Montage
Albumin Deplete Kit (Millipore, Milan, Italy), eluted with
1 M NaCl and then stabilized with NaBH4 (final concen-
tration 5mM). HSA concentration was measured by
absorbance at 279 nm (E 1% 1 cm ¼ 5.31). Samples were
then desalted on Microcon YM30 centrifugal filter devi-
ces (Millipore, Milan, Italy) by rinsing with distilled water
and then lyophilized and stored at ÿ20 C until analysis.
Lyophilized albumin (420 lg) was dissolved in 100 ll of
100mM Tris-HCl (pH 7.8) solution containing 6 M urea
and 10mM DTT, and heated at 60 C for 1 h. Cysteinyl
thiols were then blocked by the addition of IAA (20 lL
of a 200mM solution) for 60min in the dark. Residual
IAA was quenched by the addition of 20 lL of DTT and
incubation for additional 60min in the dark. The sample
was then diluted to 1mL with 50mM NH4HCO3 (pH 7.8),
and a 400 lL aliquot was digested with trypsin at a pro-
tease:protein ratio of 1:20 (w/w) at 37 C overnight. A
200 lL aliquot was then submitted to chymotrypsin
digestion at a protease:protein ratio of 1:20 (w/w) for 8 h
at 37 C in the presence of 10mM CaCl2. To stop the
protease activity (for both trypsin and trypsinþ chymo-
trypsin digestion), samples were spiked with TCA (10%
final concentration) and centrifuged at 18,000g for
10min.
Fifty microliter of the supernatants (or of the reduced
LQQCPF-adducts mixture) were injected into a quater-
nary pump HPLC system (Surveyor LC system,
ThermoQuest, Milan, Italy) connected by an ESI source
to a triple quadrupole TSQ Quantum Ultra
(ThermoQuest, Milan, Italy). The ESI source was set in
the positive-ion mode, under the following conditions:
capillary temperature 270 C; spray voltage 4.5 kV; capil-
lary voltage 12.5 V. The flow rate of the nebulizer gas
(nitrogen) was 5 l minÿ 1. The LC-ESI-MS analyses were
done in data-dependent-scan mode with precursor ion
scanning as previously reported [22] by selecting the
following product ions: m/z 242.1, 263.1 and 370.2 (colli-
sional voltage 40 V). A mass unit resolution and scan
time of 1 s were used in both quadrupoles Q1 and Q3,
and the Q1 scan range was set at m/z 300–1500. The























































adducts were then characterized in product-ion scan
mode in the following conditions: Q1 peak width 0.7,
scan time 1 s, collision energy 30 V, scan range
50–1500 m/z.
Semiquantitative measurement of LQQC(ACR)PF
adduct
The LQQC(ACR)PF adduct content was determined as
percentage in respect to the unmodified form detected
as carboamidomethylated derivative LQQC(CAM)PF due
to the HSA treatment with IAA. The relative content of
ACR modified LQQCPF was determined in Multiple
Reaction Monitoring mode by setting the following tran-
sitions:
LQQC CAMð ÞPF: precursor ion at m=z 792:5;
product ions at m=z 263:1 y2 ionð Þ
LQQC ACRð ÞPF: precursor ion at m=z 793:5;
product ion at 531:1 b4  ionð Þ
These fragments were selected from the MS/MS
spectrum obtained by analyzing the sample in prod-
uct-ion scan mode. In particular, the peak relative to
the LQQC(ACR)PF was characterized by a retention
time of 54.2min and by a molecular ion of 793.5
m/z ([MþH]þof the reduced adduct) [22].
The amount of each analyte was determined by
using a calibration curve built by using standards
prepared by incubating the native peptide LQQCPF
with IAA and ACR until the disappearance of the
native peptide [22]. The relative content
of [LQQC(ACR)PF] peptide was calculated as
it follows:
%LQQCðACRÞPF ¼ nmoles LQQCðACRÞ½
PF=nmoles LQQCðACRÞPFþ nmoles LQQCðCAMÞPF  100
Statistical analysis
Data are expressed as mean ± SD unless stated other-
wise. For statistical analysis, ANOVA, followed by the
Tukey’s post-test for multiple group comparison was
performed with the GraphPad Prism software 6
(GraphPad Prism Software, Inc., San Diego, CA), with
statistical significance set at p<0.05. Student’s unpaired
t-test was used wherever appropriate to compare var-
iations between the groups.
Results
Protein carbonyls and TBARS evaluation
Figure 1 shows the TBARS (upper panel) and protein
carbonyl (PC, lower panel) content of plasma at the
different stages of the surgical intervention. TBARS
levels were of 0.36 ± 0.11 nmol/mg protein before
anesthesia (anesthesia t0), remained almost
unchanged before and 10min after clamping (ische-
mia t0 and ischemia t10) and after 10min of ische-
mia (reperfusion t0), but significantly increased to
0.59 ± 0.07 nmol/mg after 10min of reperfusion (reper-
fusion t10). A similar trend was observed for the PC
content, which basal levels (0.17 ± 0.13 nmol/mg) did
not substantially change during ischemia but signifi-
cantly increased (to 0.75 ± 0.17 nmol/mg) after 10min
of reperfusion.
Figure 1. TBARS (upper panel) and protein carbonyl levels
(lower panel) at the different stages of hepatectomy. X-axis
indicates the following stages of the surgical intervention:
before anaesthesia (anaesthesia t0); before application of
clamps (ischemia t0); 10 min after application of clamps (ische-
mia t10); immediately after release of clamps (reperfusion t0);
10 min after start of reperfusion (reperfusion t10). Statistical
analysis: ANOVA, followed by the Tukey’s post-test. *ischemia
t0, ischemia t10 and reperfusion t0 versus reperfusion t10
(p< 0.01); **reperfusion t10 versus anaesthesia t0 (p< 0.05).























































Identification of albumin Cys34 covalent
modification by an MS precursor ion scan
approach
The oxidized isoforms of albumin, isolated by affinity
chromatography from blood samples withdrawn
before anesthesia and after 10min of reperfusion,
were detected using an off-target approach based on
an MS precursor ion scan method, as previously
reported [22]. This method is based on the isolation
and enzymatic digestion of HSA, to generate suit-
able-length peptides containing the Cys34 residue
(LQQCPF) and the corresponding adducted deriva-
tives, which are identified by LC-ESI-MS/MS in precur-
sor ion scan mode. As already reported, three ions of
the LQQCPF sequence at y2 (m/z 263.1), b2 (m/z
242.1) and b3 (m/z 370.2) were employed in precur-
sor ion scan mode to identify and characterize the
covalent modifications of Cys34. These b (where
charge is retained on the N terminal fragment) and
y (where charge is retained on the C terminal frag-
ment) ions were selected for their abundance, stabil-
ity and diagnostic value both for the native and
adducted LQQCPF, as well as for the independence
of their formation from the moiety linked to the
Cys34 residue.
Figure 2 shows a representative precursor ion scan-
ning of digested HSA isolated from the blood sample of
the subject 2 after 10min of reperfusion. The precursor
ion scan current, recorded with the product ion set at
m/z 242.1 (panel A), contains not only a peak eluting at
20.9min relative to the carboamidomethylated LQQCPF
peptide [LQQC(CAM)PF] (precursor ion at m/z 792.5) but
several other peaks. The product ions at m/z 263.1 and
370.2 (panels B and C of Figure 2) gave similar results.
To increase selectivity, the data for the precursor ion
scans were analyzed using the Boolean logic algorithm,
as already reported [22]. Briefly, for each time point, the
data for the ion current of a selected precursor ion scan
was kept and summed with the data of the subsequent
precursor ion scan only when their value were higher
than a certain threshold. The output data are reconsti-
tuted as a virtual current trace (VCT) where the dis-
played peaks are the sum of those present in all three
precursor ion scan traces, while those lacking at least
one trace are automatically discarded. The VCT of HSA
(panel D), isolated from subject 2 after 10min of reper-
fusion, displayed a main peak at m/z 792.5 with a reten-
tion time of 20.7min and a minor peak at m/z 793.4
with an increased retention time at 21.2min. Similar
results were obtained for the other subjects (data not
shown). No other adducted LQQCPF ions were
unequivocally detected.
Structural characterization of the adducted
LQQCPF peptide
In order to record the MS/MS fragment ions of the pre-
cursor ion at m/z 793.4, samples were then analyzed in
product ion scan mode. Figure 3(A) shows the selected
ion chromatogram (SIC) of digested HSA isolated from
the subject 2 after 10min of reperfusion and setting the
filter ion at m/z 793.4. The well-defined peak detectable
at 21.2min is also present in the other subjects (data
not shown). Figure 3(B) shows the MS/MS spectrum of
the ion at m/z 793.4. Since it is characterized by a set of
characteristic ions of the LQQCPF peptide (not contain-
ing the Cys34 residue), namely y1 (m/z 166.1), y2 (m/z
263.1), b2 (m/z 242.1), b2-NH3 (m/z 225.1), b3 (m/z 370.2),
b3-NH3 (m/z 353.2), this is definitively attributed to an
Figure 2. LC-ESI-MS/MS analysis (precursor ion scanning) of
trypsin/chymotrypsin digested HSA isolated after 10min of
reperfusion and before anesthesia (insert). Panels A, B and C:
precursor ion scanning currents recorded setting the product
ions at m/z 242.1, 263.1, 370.2, respectively; the precursor ion
at m/z 792.5 is attributed to the carboamidomethylated deriva-
tive [LQQC(CAM)PF]); panel D shows the VCT identifying two
peaks, attributed to LQQC(CAM)PF and to LQQCPF adduct at
m/z 793.5.























































LQQCPF backbone. Based on the molecular weight
(MW) of the precursor ion shifted by 58Da in respect to
the native peptide (m/z 735.4), the adducted moiety
was clearly attributed to the acrolein Michael adduct
reduced by the treatment with NaBH4, used as reducing
and stabilizing agent. The Cys34 modification site was
then unequivocally identified by the presence of the
diagnostic y and b adducted ions, and in particular by
the ions at m/z 531.1 (base peak) and 424.1 referring to
b4* and y3*, respectively. Final confirmation was
achieved by comparing the MW, retention time (RT) and
MS/MS fragment ions of the identified peak with those
relative to a genuine standard of LQQC(ACR)PF adduct.
Semi-quantitative analysis of LQQC(ACR)PF adduct
by MRM analysis
The relative content of ACR modified LQQCPF in respect
to the unmodified form (detected as carboamidomethy-
lated derivative [LQQC(CAM)PF] was determined in
Multiple Reaction Monitoring (MMR) mode, by setting
the diagnostic and transitions as reported in Methods.
The amount of each analyte was determined by a
calibration curve built with peculiar standards synthe-
tized in our laboratory by incubating the native peptide
LQQCPF with IAA and ACR until the disappearance of
the native peptide.
As shown in Figure 4, the relative amount of
LQQC(ACR)PF peptide in respect to the LQQC(CAM)PF,
which was of 0.6 ± 0.4% in the subjects before anesthe-
sia, increased by almost fourfold (2.3 ± 0.7%) after
10min of reperfusion (p< 0.01; t-test analysis).
Discussion
The first step of this study was aimed to quantify RCS
species during the different stages of liver hepatectomy,
and in particular before anesthesia and clamping, during
ischemia and after reperfusion. Protein carbonyl (PC)
and MDA levels did not significantly change during
ischemia and immediately after reperfusion respect to
pre-anesthesia levels but significantly increased after
10min of reperfusion (by 4.4- and 1.6-folds, respect-
ively). This trend well agrees with the well-known burst
of oxidative stress that occurs during the reperfusion
stage [30]. In particular, the oxidative damage and the
consequent formation of lipid peroxidation products
occur during reperfusion [31]. Our data confirm the
results recently reported by Tsai et al. which found a sig-
nificant MDA increase within a reperfusion period
between 3 and 30min in patients undergoing liver
transplantation [32]. The increase of RCSs determined
by the DNPH assay was higher respect to that of MDA,
which suggested that other carbonyl species are gener-
ated. These assays were performed despite their lack in
specificity, because our experience demonstrated that
using appropriate positive and negative controls, they
represent a very effective and sensitive tool for measur-
ing overall oxidative stress-induced damage.
These results prompted us to identify the main RCSs
generated during the reperfusion. Several MS-based
approaches to identify RCSs in free or adducted forms
have been reported [33,34]. We have previously found
that free plasma RCSs rapidly disappear (by almost 70%
within 5min) during reperfusion, since they form cova-
lent adducts with plasma proteins [22]. By proteomic
studies, we identified albumin as their main protein tar-
get and Cys34 as the most reactive site, whose high
nucleophilic reactivity has been clarified by molecular
modeling studies [35]. Based on these results, we aimed
at identifying the chemical structures of RCSs adducted
to Cys34. For this purpose, an off-target method, based
on precursor ion scanning was used, as already reported
Figure 3. LQQC(ACR)PF adduct characterization. Panel A: LC-
ESI-MS/MS of digested HSA isolated after 10min of reperfusion
in product ion scan mode; the ion at m/z 793.5 was set as par-
ent ion. Panel B: MS/MS spectrum relative to the ion at m/z
793.5, attributed to the Michael-adducted peptide
LQQC(ACR)PF. The asterisk indicated the adducted aa.























































[22]. Unequivocally, we identified acrolein (ACR) as the
main Cys34 RCS adduct. By using a semiquantitative
approach able to establish the relative content of ACR-
Cys34 adduct in respect to the unmodified form, we
found that the ACR-Cys34 Michael adduct was detect-
able already before clamping and significantly rose dur-
ing the reperfusion period. These results prompted us
to ascertain whether the ACR-Cys34 Michael adduct is
normally present in healthy subjects or is characteristic
of hepatic dysfunctions. ACR is a toxic and highly react-
ive a,b-unsaturated aldehyde widely distributed in the
environment as a common pollutant and generated
endogenously mainly by lipoxidation reactions. The bio-
logical effects of ACR are due to its ability to react with
the nucleophilic sites of proteins, to form covalently
modified biomolecules, which are thought to be
involved in the onset and progression of many patho-
logical conditions, such as cardiovascular and neurode-
generative diseases [36].
Others have demonstrated that ACR is released after
I/R damage in the heart [37] and in the retina of rats
[38]. Here, we first demonstrated, to our knowledge,
that ACR is the main RCS formed during liver reperfu-
sion in humans. Most likely, albumin acts as an
endogenous neutralizing agent of RCSs and hence as a
defense system against the damaging by-products
released during the oxidative stress. The amount of ACR
that escapes from the neutralizing reactions mediated
by albumin and most likely by liver glutathione (GSH),
thus acting as a damage signal in the liver, remains to
be evaluated.
Recently, it has been reported that 2-acetylcyclopen-
tanone (2-ACP) and other 1,3-dicarbonyl compounds
provide direct protection against electrophile ACR-
induced injury [39]. These compounds ionize in aqueous
solutions to form nucleophilic enolate anions, which can
form 1,4-Michael adducts with ACR, HNE and other elec-
trophilic unsaturated aldehydes involved in the oxida-
tive stress-induced injury. Recently, it has been found
that 2-ACP reduces the liver I/R damage in dose-
dependent manner by sequestering electrophilic species
and in particular ACR, as indicated by the normalization
of the I/R-altered liver histologic and biochemical
parameters [40]. Hence, our results demonstrate that
ACR is produced also in the liver I/R damage and,
although partially neutralized by albumin and endogen-
ous detoxificants, it can induce a damaging action.
In conclusion, our results clearly demonstrated that
the I/R occurring during hepatectomy induces the
release of MDA and RCSs in the blood and that ACR is
the main RCS adducted to albumin Cys34. By consider-
ing that ACR is a damaging molecule, these results offer
new target for novel molecular treatments aimed at
reducing I/R damage by agents able to sequester RCSs
and in particular a,b-unsaturated aldehydes such as
ACR.
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